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near-paralysis is also exacerbated by a paucity of current and comprehensive information on antimalarial drug efficacy in most endemic areas.
In vivo and in vitro methods for measuring drug-resistant malaria In vivo studies remain the gold standard for monitoring antimalarial drug efficacy and are the primary source of information used by policy makers to shape recommendations for malaria chemotherapy and prophylaxis. In vivo methods can be used to measure therapeutic efficacy and/or parasitological resistance, following protocols published by the World Health Organization (1973, 1996) . The outcomes of these methods are defined in the Appendix. Briefly, therapeutic efficacy is characterized by early reduction of parasite density followed by lack of fever in the presence of recurrent infection. Recurrent or persistent infection without fever is considered to be an adequate clinical response. Parasitological resistance considers only the presence, absence and level of parasite density and does not take into account clinical factors such as fever or signs of severe malaria. There is a high degree of concordance between the two methods (Plowe et al., 2001 , in press), but both probably overestimate the rate of early treatment failure/high-level resistance. Changes to improve the protocols for monitoring antimalarial therapeutic efficacy have been recommended but not yet implemented (World Health Organization, 2002) .
These standard methods for measuring antimalarial drug efficacy use a 14-day follow-up period and thus provide information only on short-term efficacy, leading some to advocate longitudinal studies of drug efficacy. In addition to measuring efficacy at 14·days, longitudinal studies measure sustained efficacy with repeated use of the same regimen over time and measure incidence of malaria episodes, reflecting how the treatment would hold up under 'real world' conditions. The incidence of treatment episodes is an outcome that is highly relevant to public health policy makers, as it reflects not only the burden of disease but also the utilization of health resources. If a drug has a moderately impaired ability to eradicate parasites, it may still have high rates of therapeutic efficacy at 14·days but have more late recrudescenses associated with higher rates of recurrent episodes of symptomatic malaria requiring treatment. Longitudinal studies also permit assessment of how pharmacokinetic properties of drugs affect the incidence of treatment episodes.
The first such longitudinal trial of antimalarial drug efficacy was a double-blind, placebo controlled trial of SP and LapDap in Kenya and Malawi that compared the cumulative number of treatment episodes and rates of treatment failure for SP and LapDap when each drug was used to treat sequential episodes of malaria over the course of one year (Sulo et al., 2002) . It was hypothesized that children receiving SP might have fewer malaria episodes than those being treated with LapDap because the long half-life of SP provided at least a month of prophylaxis against reinfection. However, this study found that despite the rapid elimination of LapDap, children treated with this drug did not have a higher incidence of malaria episodes than those treated with SP. This is probably because LapDap had higher efficacy and thus fewer late recrudescenses leading to retreatment. In effect, the potential disadvantage of lacking a long prophylactic effect due to LapDap's short half-life was offset by its better efficacy and possibly by less selection for antifolate-resistant parasites. Another recent longitudinal study found fewer treatment episodes in children treated sequentially for one year with artesunate-SP and amodiaquine-SP than in those treated with SP alone (Dorsey et al., 2002) .
Although the information gained from in vivo studies is exactly what is needed to make rational and evidence-based malaria treatment policies, standard in vivo studies remain expensive and time-consuming, and longitudinal clinical efficacy trials are even more so. Most countries in malariaendemic areas therefore conduct in vivo surveys at only a few sites and at infrequent intervals.
In vitro methods for measuring drug resistance (NguyenDinh and Payne, 1980) have proven to be even more limited in scope and suitability for surveillance. They require that venous blood with a high parasite density be quickly frozen or transported cold to a facility for parasite cultivation, the methods are laborious, and failure to establish primary parasite growth is frequent. Micro-test assays of fresh parasite isolates are subject to variation and artifact, and their reliability for different drugs varies, with particularly poor results for SP. While more-rigorous in vitro tests of culture-adapted isolates are more reproducible, the processes of freezing, thawing and adaptation to culture also introduce the possibility of selecting sub-populations of parasites, so that the parasites ultimately assayed may be genetically and phenotypically unrepresentative of the original parasite population. Nevertheless, in vitro methods are indispensable for confirming and characterizing resistance and for establishing and confirming the molecular mechanisms of resistance.
The limitations of in vivo and in vitro methods for measuring drug-resistant malaria and the elucidation of molecular mechanisms of resistance to some antimalarial drugs have led to considerable research on molecular markers for resistance. While development of field-friendly molecular assays has been rapid, validation and implementation of these assays has moved at a slower pace.
Molecular basis of chloroquine resistance
Chloroquine resistance in Plasmodium falciparum is conferred by mutations in the parasite PfCRT, a putative transporter localized to the digestive vacuole (Fidock et al., 2000b) . One mutation, Lys → Thr at codon 76 (76T), was perfectly associated with in vitro resistance in all progeny of a genetic cross between chloroquine-sensitive and chloroquineresistant parental clones and among a set of geographically Monitoring antimalarial drug resistance diverse parasite isolates (Fidock et al., 2000a) . The 76T mutation is always accompanied by a set of other pfcrt mutations, but the specific set of accompanying mutations is different in different geographic regions (Wellems and Plowe, 2001 ). This observation, and the finding that a naturally occurring parasite isolate that harbors the full complement of mutations except 76T is chloroquine sensitive but can be rendered resistant by the addition of 76T (Fidock et al., 2000b; Sidhu et al., 2002) , firmly established the key role of the 76T mutation in chloroquine resistance in vitro and suggested that the other mutations are necessary to maintain protein function (which remains unknown) in the presence of 76T. Several field studies described in a recent review have since confirmed the absolute specificity of the pfcrt K76T to clinical chloroquine resistance (Wellems and Plowe, 2001 ).
Polymorphisms in pfmdr1, which encodes the P. falciparum P glycoprotein homologue 1, modulate chloroquine resistance in mutant pfcrt-harboring parasites in vitro (Reed et al., 2000) , although their role in vivo has yet to be substantiated (Djimde et al., 2001a) . The mutations most often cited as potential contributors to chloroquine resistance are pfmdr1 N86Y and D1246Y.
Molecular basis of antifolate resistance
Pyrimethamine and chlorcycloguanil (the active metabolite of chlorproguanil) bind and inhibit dihydrofolate reductase (DHFR), and the sulfa drugs (including sulfadoxine and dapsone) inhibit dihydropteroate synthase (DHPS) by acting as analogues of p-aminobenzoic acid (PABA), a folate precursor (Foote and Cowman, 1994) . Single nucleotide polymorphisms in the genes encoding the target enzymes of the antifolate drugs have been known for several years to be associated with in vitro resistance to these drugs. In vitro resistance of P. falciparum to pyrimethamine and to chlorcycloguanil is due to specific point mutations in P. falciparum DHFR, which is encoded by a bi-functional gene (dhfr-ts) also encoding thymidylate synthase (Peterson et al., 1988 (Peterson et al., , 1990 Cowman et al., 1988; Zolg et al., 1989; Foote et al., 1990) .
The dhfr mutations alter the shape of the active site cavity where the DHFR inhibitors bind the enzyme, resulting in differential binding affinities for the different drugs. A single point mutation causing a Ser → Asn change at codon 108 causes pyrimethamine resistance with a only a moderate loss of susceptibility to chlorcycloguanil. The addition of Asn → Ile51 and/or Cys → Arg59 mutations confers higher levels of pyrimethamine resistance. Ile → Leu164, when combined with Asn108 and Ile51 and/or Arg59, confers high-level resistance to both drugs.
Point mutations in the gene encoding DHPS have similarly been associated with in vitro resistance to the sulfa drugs and sulfones. This gene (dhps-pppk) is bi-functional, also encoding hydroxymethylpterin pyrophosphokinase. Mutations associated with decreased susceptibility to sulfas include Ser → Ala436, Ala → Gly437, Ala → Gly581, and Ser → Phe436 coupled with Ala → Thr/Ser613 (Brooks et al., 1994; Triglia and Cowman, 1994; Wang et al., 1997b; Robson et al., 1992) . A Lys → Glu540 DHPS mutation was discovered in Bolivia (Plowe et al., 1997 ) and also appears to be linked with in vitro resistance to sulfa drugs (Triglia et al., 1997) . Both the DHFR and DHPS mutations occur in a progressive, step-wise fashion, with higher levels of in vitro resistance occurring in the presence of multiple mutations (Plowe et al., 1997; Wang et al., 1997a) . 
Molecular markers for resistance
These resistance-conferring mutations in parasite genes have been unequivocally linked to in vitro resistance, but demonstrating clear associations between molecular markers and clinical treatment outcomes has been less straightforward. This is due in part to the complexity of analyzing relationships between multiple mutations on different genes and the multinomial treatment outcomes listed in the Appendix and in part because treatment outcomes are affected by factors other than parasite resistance, including the host immune response (Wellems and Plowe, 2001) , micronutrient levels (van Hensbroek et al., 1995) and bioavailability and pharmacokinetics (Watkins et al., 1990) . Nevertheless, molecular markers are now available that can predict resistance to SP (Kublin et al., 2002) and chloroquine (Djimde et al., 2001a) with reasonable reliability.
In the case of chloroquine, pfcrt 76T provides a single marker for chloroquine resistance, but establishing markers for SP resistance has been more difficult. In one study, pretreatment DHFR and DHPS genotypes and treatment outcomes from a longitudinal trial of SP and LapDap for uncomplicated falciparum malaria were analyzed using a standardized system for interpreting PCR results. The presence together of all five DHFR and DHPS mutations that are found in Africa were strongly associated with SP failure and there was a statistical interaction between DHFR and DHPS mutations (Kublin et al., 2002) . This 'quintuple mutant' associated with SP treatment failure was not associated with LapDap failure. Just two mutations, DHFR Arg59 and DHPS Glu540, were over 90% sensitive and specific for the presence of all five DHFR and DHPS mutations. It is likely, but not yet proven, that DHFR and DHPS mutations that are widespread in Southeast Asia and South America would cause resistance to LapDap, but the critical mutations are either rare (DHPS A581G) or absent (DHFR I164L) in surveys of clinical samples in Africa.
Mutations in pfmdr1 (Price et al., 1999) and pfcrt (Cooper et al., 2002) have been found in laboratory studies to be associated with changes in susceptibility to artemisinin derivatives, but these in vitro differences are not associated with clinical failure, and clinical resistance has yet to be documented for this class of drug. Markers for resistance to most other antimalarial drugs are lacking because mechanisms of resistance are not yet understood at the molecular level. Molecular markers are beginning to be applied as tools for surveillance for SP and chloroquine resistance but are, at present, still primarily used as research tools. Molecular markers can provide direct and convincing evidence of selection for resistant parasites by antimalarial drug treatment (Curtis et al., 1998; Diourte et al., 1999; Nzila et al., 2000a; Djimde et al., 2001a) or prophylaxis (Doumbo et al., 2000) . Using the prevalence of molecular markers to measure selective pressure provides a means of assessing the ability of different combinations of antimalarial drugs to deter resistance to the drugs for which markers are available.
Genotype-resistance and genotype-failure indices
Although the molecular markers for chloroquine and SP resistance have been associated with in vivo resistance in many field studies, their application as tools for surveillance has been challenging, in part because the prevalence rates of molecular markers for resistance have been found to be higher than the prevalence of in vivo drug resistance in nearly all studies. This problem was addressed by studies in Mali, a country that uses chloroquine as its first-line antimalarial therapy. The investigators calculated ratios between rates of the chloroquine-resistant pfcrt genotype and therapeutic and parasitological outcomes of in vivo studies conducted at multiple sites over three years (Djimde et al., 2001b) . A genotype-resistance index (GRI) for each site was calculated by dividing the prevalence of the resistant genotype (pfcrt 76T) by the prevalence of in vivo chloroquine resistance (RI, RII and RIII) at that site. A genotype-failure index (GFI) was similarly calculated as the ratio of resistant genotype to chloroquine therapeutic failure (early and late treatment failures) at each site. The Mali studies showed that GRIs and GFIs increased dramatically with age, reflecting acquired immunity and a higher proportion of older persons who cleared parasites with the chloroquine-resistant genotype when treated with chloroquine. This observation has led to the suggestion that the ability to clear drug-resistant parasites may serve as a good model for protective immunity (Djimde et al., in press).
After controlling for age, both GRIs and GFIs ranged from 1.6 to 2.8 at all study sites over the three-year period. This study introduced the intriguing possibility that the ratios between the prevalence rates of resistant genotypes and in vivo outcomes may remain stable over time even as rates of both change, and that once these ratios, or indices, are established, molecular surveys could be used to predict in vivo treatment outcomes on a much broader scale than is possible using standard in vivo efficacy studies. Where GRIs and GFIs have been established and validated, it should be possible to collect finger-stick filter paper blood samples routinely at outlying health facilities and to transport these samples at ambient temperature to a central laboratory where the prevalence of the molecular marker can be quickly assessed for each site. Predictions of rates of resistance and failure will be somewhat imprecise but still useful. For example, in Mali it is now possible to measure the prevalence of pfcrt 76T and predict in vivo chloroquine failure and resistance rates of approximately half of the prevalence of the molecular marker. At the very least, molecular surveys can be used to target the scarce resources required to conduct in vivo studies: sites with very low rates of resistant genotypes can be safely monitored by periodic molecular surveys, while sites where the prevalence of resistance markers is high or rising might warrant confirmatory in vivo efficacy studies.
Further studies are needed to validate this model in other and more varied epidemiological settings and to refine the Monitoring antimalarial drug resistance model to determine whether molecular surveys can reliably predict high-level (RII and RIII) resistance and early treatment failures. The stability over time of the indices in Mali could be attributable to relatively small differences among sites and years in the levels of malaria transmission and acquired immunity. Similar studies at sites with much higher vs lower malaria transmission intensities or highly seasonal vs year-round transmission might yield very different results. One can speculate that just as the indices increased with age in Mali, they would be higher in settings with higher levels of transmission intensity and immunity. Where transmission is very low, few persons might be expected to clear chloroquine-resistant parasites when treated with chloroquine, so the prevalence rate of in vivo resistance would approach that of pfcrt 76T, yielding very low GRIs and GFIs; in a setting of much higher transmission and immunity, most people may have enough immunity to clear these resistant infections, resulting in higher GRIs and GFIs even after adjusting for age. Alternatively, if GRIs and GFIs are found to be similar and stable in such different settings, the model would be far more useful in that indices would not have to be established in each setting before they could be applied there.
It will also be important to validate this model with other antimalarial drugs, most importantly SP. If ratios between the prevalence rate of the two mutations that predict the presence of quintuple DHFR and DHPS mutants and the prevalence of SP parasitological resistance and treatment failure are found to be stable after adjusting for age and at different sites with different epidemiological characteristics, the GRI and GFI model may provide a good tool for mapping SP resistance. This would be useful not only where SP is already being employed, to monitor for declining efficacy, but where SP is being considered as a replacement for chloroquine.
Monitoring resistance after cessation of drug use
If removing a drug from use were to result in the disappearance of parasites resistant to that drug, the possibility of rotating the limited number of safe, effective and affordable antimalarial drugs could be considered. Removing antimicrobial drug pressure may or may not compromise the fitness of resistant microorganisms and result in selection of drug-sensitive phenotypes (Levin et al., 2000; Enne et al., 2001) . Incomplete withdrawal of the drug, cross-resistance to other drugs and compensatory mutations that reduce the cost of resistance to the fitness of the resistant microbe without jeopardizing the resistance itself (Sherman et al., 1996) may allow resistance to persist even after an antimicrobial drug has been withdrawn from use.
In 1993, Malawi became the first sub-Saharan African country to switch from chloroquine to the antifolate combination SP as the first-line antimalarial nationwide (Bloland et al., 1993) . Since 1993, SP has been the only treatment for uncomplicated malaria available in government health facilities, where it is dispensed without prescription. Chloroquine is legally available only by prescription, and a national information campaign was largely successful in convincing health practitioners and the public to accept SP as the standard treatment for malaria. Some other eastern and southern African countries, including Kenya in 1999 (Shretta et al., 2000) , have attempted to institute similar changes in national drug policy in the face of rising chloroquine resistance, with more mixed results.
Recent studies have found that the cessation of chloroquine use in Malawi was followed by reemergence and predominance of chloroquine-sensitive P. falciparum. The prevalence of the chloroquine-resistant pfcrt 76T genotype decreased steadily from 85% in 1992 to 13% in 2000 in Blantyre, a large city in central Malawi. In 2001, chloroquine cleared 100% of 63 asymptomatic P. falciparum infections, no isolates were resistant to chloroquine in vitro, and no infections with the chloroquine-resistant pfcrt genotype were detected (Kublin et al., 2003) . This same study found that in 1999, 92% of P. falciparum infections carried this mutation in neighboring Zambia, where chloroquine remains the firstline drug. Another study found a 17% prevalence of pfcrt 76T in 1998 and only 2% in 2000 in a district further north in Malawi (Mita et al., 2003) , confirming that the withdrawal of chloroquine from Malawi has resulted in the return of chloroquine-sensitive falciparum malaria there. This is most likely explained by a cost to the fitness of the parasite of the chloroquine resistance-conferring pfcrt mutations and selection for parasites with wild-type pfcrt in the absence of chloroquine drug pressure, although this remains to be demonstrated.
These studies provide a rationale for conducting controlled trials of chloroquine efficacy in areas where chloroquine use has been substantially reduced for a period of years. If such trials confirm a return of chloroquine's clinical efficacy, governments can consider withdrawing chloroquine and switching to other drugs on an interim basis, knowing that they may be able to later reintroduce chloroquine, which is unparalleled in its safety and low cost. As such antimalarial drug policy changes are considered and implemented, careful and integrated use of in vivo, in vitro and molecular assays for resistance have the potential to provide timely and practical information to help guide these policies. Already, molecular surveys have been integrated into the National Malaria Control Program in Mali and used to provide timely advice in a malaria epidemic in northern Mali (A. A. Djimde, A. Dolo, S. Diakite, A. Ouattara, C. V. Plowe and O. K. Doumbo, unpublished) . Laboratories capable of performing basic molecular assays are well established in many African countries. The challenge now for scientists and policy makers is to work together to exploit advances in our understanding of the molecular mechanisms of drug-resistant malaria in order to make rational and informed decisions about malaria chemotherapy and prophylaxis policies.
Appendix. Definitions of in vivo therapeutic efficacy and parasitological resistance Therapeutic efficacy outcomes Early treatment failure:
danger signs or severe malaria on post-treatment days 1, 2 or 3, with parasitemia; axillary temperature of >37.5°C on day 2 with parasitemia greater than the day 0 level; axillary temperature of >37.5°C on day 3 in the presence of parasitemia; or parasitemia on day 3 of >25% of day 0 level.
Late treatment failure:
failure to meet any of the criteria for early treatment failure; development of danger signs or severe malaria in the presence of parasitemia during days 4-14; or axillary temperature of >37.5°C in the presence of parasitemia during days 4-14.
Adequate clinical response:
failure to meet any of the criteria of early or late treatment failure; absence of parasitemia on day 14 irrespective of temperature; or axillary temperature of <37.5°C irrespective of the presence of parasitemia.
Parasitological resistance outcomes RIII: no reduction in parasitemia, or reduction to >25% of day 0 level, by day 3.
RII: reduction in parasitemia to <25% of day 0 level without clearance leading to re-treatment or followed by persistent parasitemia.
RI: initial clearance of parasites indicated by negative thick smear after day 0, with subsequent positive thick smear by day 14.
Sensitive: clearance of parasites by day 14 with no recurrence of parasitemia.
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